Researchers at the University of Hawaii have developed a new gene editing technology that can efficiently deliver healthy genes to the body. This method addresses limitations of current methods and has shown success rates of up to 96%, potentially leading to faster and more affordable treatments for various genetic diseases.
Researchers have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease. The treatment approach may represent a potential long-term universal treatment for MSUD.
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
The LENN system protects and efficiently releases NA therapies within the cytoplasm of target cells, overcoming low efficiencies and immune system clearance issues. It is biomanufacturable, biodegradable, and highly tunable, targeting a variety of cells depending on their tumor-specific surface markers.
Researchers have developed two new methods to produce circular RNAs, which can silence genes and serve as templates for making therapeutic proteins. These circular RNAs display enhanced stability and biological activity in heart muscle cells and neurons.
Researchers at Åbo Akademi University have discovered a crucial protein, TLNRD1, that helps maintain blood vessel stability in the brain. The study highlights the potential for targeted molecular therapies to improve patient outcomes in CCM disease.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
Researchers discovered a unique probiotic strain, Bifidobacterium bifidum BB1, that strengthens intestinal barrier function and protects against harmful bacteria. This strain may lead to the development of novel therapies for patients with inflammatory bowel disease and other inflammatory conditions.
A recent study found that Chinese patients with ovarian cancer often carry a specific variant of the RAD51D gene, which can promote tumor growth. The variant also makes these patients more sensitive to PARP inhibitors, leading to a favorable prognosis and potential new treatment methods.
Researchers developed a treatment approach using lipid nanoparticles to deliver mRNA therapy for MSUD, extending survival and reducing serum leucine levels. The study also identified a novel AAV variant with desirable biodistribution properties for targeting peripheral organs.
A new platform called CellTracksColab has been introduced to simplify cell tracking data analysis, enabling researchers to study cell movement and behavior. The tool provides a user-friendly interface for analyzing complex data, leading to new insights into diseases such as cancer metastasis.
The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...
Researchers at Dana-Farber Cancer Institute investigated the role of physical forces in enhancing T cell performance. They found that applying piconewton forces can improve digital cytotoxic T lymphocytes' ability to recognize and destroy altered cells, leading to better immunotherapies.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A new study provides first-of-its-kind data on the pharmacokinetics and safety of intravenous remdesivir in treating SARS-CoV-2 coronavirus in pregnant women. The research reveals that no dose adjustments are necessary for remdesivir when used in pregnant women, with no safety concerns or adverse pregnancy outcomes identified.
Researchers studied three polyploid plant species that successfully adapted to extra DNA and found distinct molecular solutions. The study identified the CENP-E molecule as a promising target for killing polyploid cancers. Additionally, 'meiosis genes' were found to play a crucial role in rapid adaptation to polyploidy.
A new index uses inflammatory cell proportions to predict tissue healing and outcomes in patients with ulcerative colitis. The index, called the inflammatory cell enumeration index (ICEI), was developed by analyzing data from 220 patients who achieved healing.
Glial cells play a significant role in Alzheimer's disease, producing amyloid beta and contributing to plaque formation. Researchers discovered that knocking out BACE1 enzyme in oligodendrocytes reduced plaque formation by 30%, opening up new avenues for therapies.
Researchers have developed a new class of synthetic polymers that effectively combat fungal infections by attacking the cells in multiple ways. These compounds mimic naturally occurring peptides and offer potential for sustainable treatment options with improved survival rates.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers developed a dissolvable microneedle patch to deliver immunomodulatory microparticles containing bifunctional molecules, such as azithromycin, to treat periodontitis. The patch demonstrated therapeutic outcomes by suppressing bacterial growth and modulating immune responses in both in vitro and in vivo studies.
Researchers at the University of Houston have developed two nasal sprays, NanoSTING and NanoSTING-SN, to prevent respiratory virus transmission. NanoSTING is an immune activator that can protect against multiple viruses, while NanoSTING-SN is a pan-coronavirus vaccine that can prevent transmission to unvaccinated individuals.
Scientists at St. Jude Children's Research Hospital identified two chemokines, CXCL8 and CXCL16, expressed by osteosarcoma that improved CAR T-cell homing. Modified cells expressing these chemokine receptors showed enhanced infiltration into tumors, leading to prolonged survival in a model of metastatic disease.
A national multicenter study found that younger women and those with non-malignant diseases had a higher chance of successful pregnancies after allogeneic hematopoietic cell transplantation. The study analyzed data from 2,654 women who underwent transplantation between 2003 and 2018.
Researchers have developed a new therapy called PIPE-307 that targets an elusive receptor on certain cells in the brain, prompting them to mature into myelin-producing oligodendrocytes. This could potentially reverse damage caused by multiple sclerosis, leading to improved movement, balance, and vision.
The study found that 29% of patients experienced progression-free survival at five years and 40% achieved overall survival. However, important survivorship issues were identified, including nonrelapse mortality rates of 16.2%, with over half occurring beyond two years post-treatment.
A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
A new zwitterionic polymer complex has been developed to deliver plasmid DNA into skeletal muscle, achieving widespread gene expression in mice. This breakthrough could lead to new therapies for serious muscular diseases.
Researchers found correlations between MIF and DDT levels with patient survival outcomes in melanoma patients. Higher CD74:MIF and CD74:DDT levels were associated with improved survival and enrichment of inflammatory markers.
A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
Scientists improve stability and bioavailability of mRNA nanocarriers using triphenylphosphonium, leading to increased protein production in tumor tissues. The TPP-based system also shows higher mRNA levels in blood after 30 minutes compared to amine-based micelles.
A preclinical study suggests that knocking out CD5 on CAR T cells boosts their anti-tumor efficacy against various cancers, including solid tumors. The researchers found that CD5 deletion enhances the function of CAR T cells by reining in immune responses and increasing cancer-cell-killing activity.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
Researchers found that subretinal adeno-associated virus 8 injections trigger proinflammatory T-cell responses, but co-injection of immunodominant peptides can modulate the immune system. This study suggests a new approach to AAV gene therapy for retinal diseases.
The FDA approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy, marks a major advancement in personalized cancer treatment. Moffitt researchers are expanding this therapeutic approach to treat other solid tumor cancer types, such as lung, sarcoma, cervical and bladder.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers at Memorial Sloan Kettering Cancer Center found that the spatial arrangement of three immune cells - dendritic cell, cytotoxic T cell, and helper T cell - is crucial for effective killing of cancer cells. This discovery has immediate therapeutic implications for immunotherapy treatments.
A new CAR-T cell therapy targeting CD22 has shown significant improvement in patients with large B-cell lymphoma, with over half experiencing a complete response. The therapy, which targets a different protein on the surface of cancer cells, has improved outcomes for patients who have failed previous treatments.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
A new immune cell therapy has been shown to delay ALS onset and extend survival in mice, as well as reduce inflammation in an individual with the disease. In a phase I clinical trial, the therapy is now set to be tested on humans.
Researchers discuss the critical role of the retinal pigmented epithelium in human vision and its susceptibility to aging. The study highlights the importance of understanding molecular and cellular mechanisms driving age-related pathological changes in vision decline.
Researchers identified a population of stem-like cells that initiates and maintains Group 3 medulloblastoma (Gr3-MB) in the developing brain. Eliminating these cells led to tumor shrinkage in preclinical models, suggesting a novel approach for treating children with Gr3-MB.
Researchers at the University of Notre Dame have developed a wireless LED device that can be implanted to treat deep-seated cancers. The device, combined with a light-sensitive dye, destroys cancer cells and triggers an immune response against them.
A systematic review and meta-analysis of CAR T cell therapy reveals that infections are the main driver of non-relapse mortality in patients. The study analyzed reports from over 7,600 patients across 18 clinical trials and found that infections accounted for half of all reported non-relapse related deaths.
LNP-mRNA therapy faces challenges like targeting, quality control, and safety concerns. Researchers are optimizing dosage, addressing CMC requirements, and enhancing targeting efficiency to improve therapeutic outcomes.
Researchers have identified a novel type of T cell that can recognize and respond to multiple bacterial strains in the gut. This breakthrough finding has significant implications for treating diseases such as cancer and inflammatory bowel disease. The discovery was made by Kazuki Nagashima, winner of the NOSTER & Science Microbiome Prize.
Immunotherapies have revolutionized HCC treatment by enhancing the immune system's ability to recognize and destroy cancer cells. Key approaches include checkpoint inhibitors, targeted therapies, and advanced cellular immunotherapies.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new biomarker has been discovered that can help predict which patients with clear cell renal cancer are at higher risk of recurrence. The 15-gene signature was found to be independently associated with worse disease-free survival and disease-specific survival in two large validation datasets.
Researchers at Georgia Tech have developed a method to improve adoptive T-cell therapy using nanowires to deliver therapeutic miRNA to naïve T-cells. This approach retains the cells' naïve state, making them more effective disease fighters when infused back into patients.
Researchers at MD Anderson Cancer Center have identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), reducing cellular senescence and tissue inflammation. TERT restoration also spurred new neuron formation with improved memory and enhanced neuromuscular function.
Recent research reveals that targeting senescent cells as the cause of aging is not accurate. Instead, these cells have positive health impacts and may pose risks if targeted therapeutically.
Researchers at EPFL have published an open-source project Tabulae Paralytica, providing a comprehensive understanding of spinal cord injury biology. The study identifies specific neurons and genes involved in recovery and proposes a successful gene therapy derived from its discoveries.